Emily Titus's Biography

Emily Titus, Director, Technology Development, Centre for Commercialization of Regenerative Medicine (CCRM)

Emily is Director, Technology Development in the Advance labs at CCRM, with a focus on cell reprogramming, genome engineering and pluripotent stem cell differentiation. She obtained her PhD from the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, where she used a combination of laboratory and bioinformatics approaches to define and interpret gene regulatory networks controlling embryonic stem cell fate decisions. At CCRM, Emily’s team develops and evaluates technology related to iPSC derivation, genome engineering, directed differentiation, translation of bench scale protocols to scalable platforms, and works on projects that advance the commercialization of stem cells.